NCT03409367Completed
A Community-based Assessment of Skin Care, Allergies, and Eczema
Source: ClinicalTrials.gov · Last updated 15 Aug 2025
Brief summary (registry, in English)
Atopic dermatitis (AD) affects over 9 million children in the U.S. and often heralds the development of asthma, food allergy, skin infections and neurodevelopmental disorders. Recent advances identify skin barrier dysfunction to be the key initiator of AD and possibly allergic sensitization. Our central hypothesis is that daily emollient use from birth can prevent the development of AD in a community setting and into newborns unselected for risk. The results of a community-based clinical trial utilizing a pragmatic trial design will be immediately applicable to the population at large and will establish a new standard of care for all newborns.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 1260 (actual)
- First submitted
- 11 Jan 2018
- Start date
- 16 Jul 2018
- Primary completion date
- 29 Sept 2023
- Lead sponsor
- Oregon Health and Science University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT03409367
What you commit to
- Study type: Interventional
- Participants enrolled: 1260
- From 16 Jul 2018 to the primary completion date, 29 Sept 2023
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Infant has an immunodeficiency genetic syndrome such as Wiskott-Aldrich Syndrome or Severe Combined Immunodeficiency Syndrome.
Age
- Infant was born at less than 25 weeks gestational age.
Other
- Infant has established eczema as diagnosed by the primary healthcare provider at clinic site of enrollment per parent report.
- Infant has known adverse reaction to petrolatum-based emollients.
- Infant has extremely low birth weight (less than 1000g or 2.2 lbs at birth).
- Infant has a sibling enrolled in the study.
- Parent is unwilling or unable to comply with study procedures.
Who the study is looking for
- Parent can provide electronic signed and dated informed consent form.
- Parent is willing and able to comply with all study procedures for the duration of the study.
- Parent is a primary caretaker of an infant 0 to 2 months of age.
- Parent is 18 years of age or older at time of consent.
- Parent can speak, read, and write in English or Spanish.
- Parent has a valid e-mail address or phone that can receive text messages
- Parent has reliable access to the internet.
- Infant is a patient of a participating Meta-LARC clinic site at the time of consent.
Age in the registry: 1 day to 63 days · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Denver Coordinator of this site? Confirm its status | Denver | United States | Unknown status |
| Duke University Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| University of Wisconsin - Madison Coordinator of this site? Confirm its status | Madison | United States | Unknown status |
| Oregon Health Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.